NCT00524576View on ClinicalTrials.gov

Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

November 28, 2007

Primary Completion Date

May 14, 2008

Study Completion Date

May 14, 2008

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix™-B

One dose (10µg Hepatitis B surface antigen (HBsAg))

Trial Locations (3)

1200

GSK Investigational Site, Brussels

2145

GSK Investigational Site, Westmead

2610

GSK Investigational Site, Wilrijk

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00524576 - Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine | Biotech Hunter | Biotech Hunter